Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Koru Medical Systems Inc. (KRMD:NASDAQ), powered by AI.
Koru Medical Systems Inc. is currently trading at $3.94. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Koru Medical Systems Inc. on Alpha Lenz.
Koru Medical Systems Inc.'s P/E ratio is -69.0.
“Koru Medical Systems Inc. trades at a P/E of -69.0 (undervalued) with modest ROE of -15.6%. 3Y revenue CAGR of 13.8% highlights clear growth momentum.”
Ask for details →Koru Medical Systems Inc. is a medical technology company focused on the development and manufacturing of innovative drug delivery systems. Its primary function is to design and supply flexible infusion technologies that aim to enhance patient care and experience. The company is renowned for its Freedom syringe infusion system, a portable and user-friendly device that is often used for subcutaneous administration of biologics and other specialty drugs. This system caters to patients with chronic conditions, allowing them to manage their treatments outside of traditional healthcare settings, thereby improving convenience and accessibility. Koru Medical Systems is an influential player in the medical devices industry, significantly impacting the healthcare sector by enabling at-home therapies and supporting the growing trend of self-administration. The company's solutions address the increasing demand for personalized and efficient healthcare, underscoring its relevance in the market by promoting patient-centric care and operational efficiency in drug delivery.
“Koru Medical Systems Inc. trades at a P/E of -69.0 (undervalued) with modest ROE of -15.6%. 3Y revenue CAGR of 13.8% highlights clear growth momentum.”
Ask for details →Koru Medical Systems Inc. (ticker: KRMD) is a company listed on NASDAQ in the Healthcare sector (Medical Instruments & Supplies). It has approximately 80 employees. Market cap is $182M.
The current price is $3.94 with a P/E ratio of -68.98x and P/B of 10.67x.
ROE is -15.58% and operating margin is -7.23%. Annual revenue is $41M.